← Back

vTv Therapeutics Inc

vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral small molecule drug candidates for diabetes and other chronic diseases. Its lead candidate, cadisegliatin (TTP399), is an orally administered, liver-selective glucokinase activator in Phase III clinical trials for type 1 diabetes. The company also has a license agreement with Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.

Country
Price · split & dividend adjusted
News & notes moving VTVT
VTVT

vTv Therapeutics grants 23,500 stock options to two new employees

vTv Therapeutics granted 23,500 stock options to two non-executive employees as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4). The options have a weighted average exercise price of $31.95 per share, vest over four years with 25% after one year and the remainder quarterly over 36 months, and carry a 10-year term. The grants were made under the company's 2026 Inducement Plan.
GlobeNewswire·52dRead more →